(Q38263575)

English

Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25353620%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

Europe PubMed Central

Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25353620%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Omar Abdel-Rahman

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25353620%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Omar Abdel-Rahman

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

publication date

29 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25353620%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Expert Review of Anticancer Therapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25353620%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25353620%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25353620%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

235-245

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25353620%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Gastric cancer: global pattern of the disease and an overview of environmental risk factors

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Targeted therapy for advanced esophagogastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Molecular classification of gastric cancer: a new paradigm

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Tyrosine kinase receptor indistinguishable from the c-met protein

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Targeting MET in cancer: rationale and progress

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

MET signalling: principles and functions in development, organ regeneration and cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

A mouse model of activating Met mutations

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

High expression of the Met receptor in prostate cancer metastasis to bone

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

c-met proto-oncogene expression in benign and malignant human prostate tissues

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Value of c-Met for Predicting Progression of Precancerous Gastric Lesions in Rural Chinese Population

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Prognostic value and clinical pathology of MACC-1 and c-MET expression in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Expression of MACC1 and c-Met in human gastric cancer and its clinical significance

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

MET amplification as a potential therapeutic target in gastric cancer.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Phosphatidylinositol 3-kinase Contributes to Erk1/Erk2 MAP Kinase Activation Associated with Hepatocyte Growth Factor-induced Cell Scattering

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.974564

21 January 2018

Identifiers

10.1586/14737140.2014.974564

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25353620%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25353620%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38263575&oldid=1510066980"